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ABSTRACT 
Diabetes mellitus relates a metabolic disorder of collective aetiology which is characterized by chronic hyperglycaemia caused due to 
disturbances of carbohydrate, lipid and protein metabolism due to impaired β cell function of pancreas or insulin resistance or both. Dipeptidyl 
peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of antidiabetic that show favorable results in improving glycemic control 
with a minimal risk of hypoglycemia and weight gain. Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for 
the management of type 2 diabetes mellitus. Teneligliptin, characterized by a "J-shaped" structure formed by five consecutive rings which give 
unique binding characteristics, reflect in higher potency than other dipeptidyl peptidase 4 inhibitor. Teneligliptin is a novel antihyperglycemic 
agent with a preferable profile in terms of long-term efficacy and safety in patients with type 2 diabetes. 
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Introduction: 
Diabetes mellitus (DM) is probably one of the oldest diseases 
known to man. Diabetes is the increasingly growing 
metabolic threat of our contemporary era. Diabetes was first 
described in an Egyptian manuscript from 1500 BC, 
mentioning “too great emptying of the urine”. Later on, 
Indian physicians described the disease and classified it as 
honey urine by the fact that ants were attacked by patient’s 
urine. The term “diabetes” or “to pass through” was first used 
in 250 BC by the Greek Apollonius of Memphis1. There were 
more than 73 million cases of diabetes in India in 20172 and 
achieved undesired title ‘centre for diabetes in world’ with 
millions populations and many more rising3. 
Complications of diabetes are a major cause leading to 
morbidity and mortality in India and type 2 diabetes mellitus 
(T2DM) is thus considered as one of the major growing 
epidemics4, 5. Diabetes affects many organs, and 
complications due to high blood glucose are an important 
cause of disability, reduced quality of life, and premature 
death6. For the proper management of the disorder, the 
medicament has to be taken at regular intervals of time, 
lifelong. Conventional antidiabetic oral dosage forms offer no 
control over drug delivery, leading to fluctuations in plasma 
drug concentration and causes irregular glucose level in the 
patient’s body. This shows that there are most requirements 
of the antidiabetic drugs to maintain the blood glucose level 
over the extended period of time for better therapeutic 
efficacy of drug. 
Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently 
emerged as a new class of antidiabetic that show favorable 
results in improving glycemic control with minimal risk Type 
2 diabetes mellitus complications. Teneligliptin is a novel 
oral dipeptidyl peptidase-4 inhibitor for the treatment of 
type 2 diabetes mellitus (T2DM) having a unique structure 
characterized by five consecutive rings, which produce a 
potent and long-lasting effect7.Teneligliptin is currently used 
in cases showing insufficient improvement in glycemic 
control even after diet control and exercise or a combination 
of diet control, exercise, and oral hypoglycemic drugs used 
include Biguanides, Sulphonylureas8, 9. 
Teneligliptin was originally synthesized by Mitsubishi 
Tanabe Pharma Corporation (Osaka, Japan) and was the first 
drug of its kind to be synthesized in Japan. Mitsubishi Tanabe 
Pharma Corporation and Daiichi Sankyo Co, Ltd, (Tokyo, 
Japan) 
The economic costs of T2DM10 
There is a substantial economic impact of diabetes on 
individuals, society, health care system, employer, and even 
the country in terms of loss of productivity. Reported 
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evidence suggests that there is a strong and direct economic 
impact of T2DM on the lives of people in lower income 
settings. In developing countries, where health care 
expenditure is many times out-of-pocket, an economic 
impact of T2DM is huge and may affect the long-term 
outcome of T2DM. There should be affordable medical 
treatment available to all. The cost of medicine should not be 
a barrier for health care. In this scenario, availability of 
economical DPP-4 inhibitors such as teneligliptin is a 
positive step. 
Role of Teneligliptin in Type-2 Diabetes Mellitus 
therapy 
Dipeptidyl peptidase-4 (DPP-4) work by increasing levels of 
active glucagon-like peptide-1 (GLP-1), thereby promoting 
insulin secretion, in a blood glucose-dependent manner, and 
hence decreasing glucose levels while minimizing the risk of 
hypoglycaemia. DPP-4 inhibitors are recommended in 
international guidelines11. Meta-analyses have suggested 
that DPP-4 inhibitors may be more potent in reducing HbA1c 
levels in Asian T2DM patients than in non-Asian patients12, 13. 
Published evidence suggests that even 1% reduction in 
HbA1c reported significant reduction in the risk of long-term 
complications associated with T2DM14.   
Incretin hormones, namely glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic polypeptide (GIP), are 
released from enteroendocrine cells and enhance insulin 
secretion15, 16. Incretins are rapidly inactivated by the 
enzyme dipeptidyl peptidase-4 (DPP-4), and have a very 
short half-life (t1/2) as a result. DPP-4 inhibitors increase 
the levels of active GLP-1 and GIP by inhibiting DPP-4 
enzymatic activity; thus, in patients with diabetes, these 
inhibitors improve hyperglycemia in a glucose-dependent 
manner by increasing serum insulin levels and decreasing 
serum glucagon levels15, 17, Therefore, incretin-related agents 
such as DPP-4 inhibitors are promising drugs that can 
decrease glucose fluctuations in diabetic patients and have 
emerged as a new class of antidiabetic. Rise in new beta-cells 
and inhibition of their apoptosis is seen with Dipeptidyl 
peptidase-4 (DPP-4) which can potentially improve the 
disease pathogenesis. The American Diabetes Association 
(ADA) guidelines recommend Dipeptidyl peptidase-4 (DPP-
4) as second-line therapy after metformin. Therefore, DPP-4 
can be the choice of drugs in every T2D patient18. 
 
 
Figure 1: Structural heterogeneity of dipeptidyl peptidase-4 (DPP-4) inhibitors. 
 
Figure 2: Chemical structure of teneligliptin. 
Gorde et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):742-747 
ISSN: 2250-1177                                                                                  [744]                                                                                 CODEN (USA): JDDTAO 
Chemistry of Teneligliptin19, 20 
Despite their common mechanism of action, DPP-4 
inhibitors show marked structural heterogeneity (Figure 1). 
DPP-4 inhibitors may be classified into peptidomimetic (i.e., 
sitagliptin, vildagliptin, saxagliptin, and anagliptin) and non-
peptidomimetic (i.e., alogliptin and linagliptin) subtypes. 
Teneligliptin, {(2S, 4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-
5-yl) piperazin-1-yl] pyrrolidin-2-yl} (1, 3-thiazolidin-3-yl) 
methanone hemipentahydrobromide hydrate exhibits a 
unique structure that is characterized by five consecutive 
rings (Figure 2) and is peptidomimetic. An X-ray co-crystal 
structure of teneligliptin with DPP-4 demonstrates that the 
key interaction occurs between the phenyl ring on the 
pyrazole and the S2 extensive subsite of DPP-4, which not 
only enhances the potency of the drug but also increases its 
selectivity. 
Pharmacokinetic and pharmacodynamic 
properties of Teneligliptin21 
The plasma concentrations of teneligliptin after the admin-
istration of teneligliptin at dosages of 10 or 20 mg once daily 
for 4 weeks revealed a median time to maximum 
concentration (Cmax) of 1.0 hour in both groups and a mean 
t1/2 of 20.8 and 18.9 hours, respectively. The maximum 
percentage of the inhibition in plasma DPP-4 activity was 
achieved within 2 hours after administration and was 81.3% 
and 89.7% in the 10 and 20 mg teneligliptin groups, 
respectively. A pharmacokinetic/pharmacodynamic study 
revealed that teneligliptin inhibits DPP IV activity over 24 
hours, with elevation of activated glucagon-like peptide 1 
(GLP-1) levels and the resulting suppression of postprandial 
hyperglycemia at all three daily meals. Monotherapy for 12 
weeks significantly decreased hemoglobin A1c (HbA1c), 
fasting blood glucose, and 2-hour postprandial blood glucose 
levels in patients with type 2 diabetes. The therapeutic 
efficacy of teneligliptin over 52 weeks was confirmed not 
only as monotherapy but also as add-on therapy in patients 
with inadequately controlled blood glucose levels with 
sulfonylureas or thiazolidinediones. 
Metabolism and excretion of Teneligliptin 22 
Teneligliptin has dual mode of excretion i.e., hepatic and 
renal routes. About 34.4% of teneligliptin is excreted 
unchanged via the kidney and the remaining 65.6% 
teneligliptin is metabolized and eliminated via renal and 
hepatic excretion; 216 hours after the administration of 14C-
labeled teneligliptin (20 mg), the cumulative excretion 
percentages of radioactive teneligliptin in urine and feces 
were 45.4% and 46.5%, respectively. Teneligliptin is 
eliminated via excretion with a half-life of 24.2 hours in 
human plasma from the kidney and metabolism involving 
certain enzymes.  
Teneligliptin - Stronger DPP- 4 Inhibitor than 
other DPP- 4 Inhibitor 7, 22, 23 
Teneligliptin might have stronger inhibitory action against 
DPP-4 than other DPP- 4 inhibitors, because the plasma 
DPP-4 activity was significantly decreased after switching to 
teneligliptin. Teneligliptin has a unique structure, and binds 
to the S1, S2 and S2 extensive subsite of the DPP-4 enzyme, 
leading to enhanced potency and selectivity, and it is also a 
class 3 DPP-4 inhibitor. Additionally, binding of teneligliptin 
to the S2 extensive site, apartfrom the S1 and S2 sites, 
imparts stronger inhibitory action on the DPP-4 enzyme. 
Furthermore, teneligliptin was reported to have the J-shaped 
anchor-lock domain, strong covalent bonds with DPP-4 and 
more extensive S2 extensive binding, showing its higher 
inhibitory activity. 
 
Table 1 Summary of the interactions of various DPP-4 inhibitors with DPP-4 enzyme19, 22, 24, 25 
Class DPP-4 
inhibitors 
Binding at 
DPP-4 
Details 
I Vildagliptin and saxagliptin S1 and S2 
subsites 
• Most fundamental level of interaction 
• Cyanopyrrolidine moieties bind with S1 
• Hydroxy adamantly group binds with S2 
• Saxagliptin has fivefold higher activity than vildagliptin 
II Alogliptin and linagliptin S1, S2, S1′, 
and S2′ 
subsites 
• Additional binding to S1′ and S2′ 
• Alogliptin binds to S1, S2, and S1′ 
• Linagliptin binds to S1, S2, S1′, and S2′ 
• Linagliptin had eightfold higher activity than alogliptin 
III Sitagliptin and teneligliptin S1, S2, 
and S2 
extensive 
subsites 
• Binds S1, S2, and S2 extensive 
• Teneligliptin has fivefold higher activity than sitagliptin, 
because of: 
• Teneligliptin has favorable (J-shaped) 
structure leading to small loss of energy during binding with 
DPP-4 
• Teneligliptin forms hydrogen bond with DPP-4 
• Teneligliptin has more extensive binding at “S2 extensive” site 
than sitagliptin 
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A crystallographic study suggested that the key interaction 
between a phenyl ring on teneligliptin and the S2 extensive 
subsite of DPP-4 enhances the drug's potency and may 
increase its selectivity12.Teneligliptin differs from other 
clinically used DPP-4 inhibitors, including sitagliptin, with 
regard to its elimination pathway. With teneligliptin, this 
involves both hepatic and renal excretion; whereas other 
DPP-4 inhibitors are typically eliminated by renal excretion 
only13.This may reflect the potency of teneligliptin as an 
inhibitor of DPP-4, based on its unique binding 
characteristics derived from its chemical structure. 
Teneligliptin in the Management of T2DM 
complications: 
In adults, 20 mg of teneligliptin may be orally administered 
once daily. If this dosage is insufficient, the dosage is 
increased to 40 mg once daily. 
Effect of Teneligliptin on blood glucose level26, 27 
Treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors, 
which are incretin-related antidiabetic agents, is widely 
accepted in clinical practice because of their low risk of 
hypoglycemiaand their beneficial effect on glucose control. 
To assess blood glucose control over 24 hours and the safety 
of teneligliptin at 10 and 20 mg doses, a randomized, double-
blind, placebo-controlled, parallel-group study was 
conducted at four locations in Japan, results indicate that the 
once-daily administration of teneligliptin before breakfast 
improved blood glucose control, even at dinnertime. 
Effect of Teneligliptin on insulin7, 28  
Patients with T2DM receiving insulin therapy, with or 
without other antidiabetic agents, the addition of 
teneligliptin reported significant improvement in diurnal 
glycemic control and significant reductions in glucose 
fluctuations in 24-hour periods without increasing the risk 
of hypoglycaemia. 
Effect of Teneligliptin on glucagon7 
The postprandial glucagon levels significantly decreased 
after breakfast and lunch as well as after dinner in the 
teneligliptin-treated group compared with the 
corresponding values in the placebo group. 
Renoprotection of Teneligliptin in type 2 diabetes 
patients with diabetic kidney disease23, 29 -33 
Diabetic kidney disease (DKD), which is a diabetic vascular 
complication, is recognized as a major leading cause of end 
stage renal disease. Glucose control is fundamentally 
important for the prevention of DKD, as well as the control 
of blood pressure (BP) using renin–angiotensin system 
(RAS) inhibitors. However, hypoglycemia should be avoided, 
because hypoglycemia is closely related to increased 
mortality, which is associated with an increased incidence of 
cardiovascular disease. In addition to their glucose-lowering 
effect, DPP-4 inhibitors have renoprotective effects, which 
are mainly a reduction in albuminuria, independent of the 
glucose-lowering effect. Teneligliptin has strong and long 
DPP-4 inhibitory effects, and no dose adjustment may be 
required, even if the patient has renal function decline. 
Because 34.4% of the administered dose of teneligliptin is 
excreted unchanged through the renal route, whereas 65.6% 
is metabolized and eliminated through the hepatic and renal 
routes. In addition, the distribution of teneligliptin to the 
kidney is high because of its lipophilicity, possibly showing a 
renoprotective effect. DPP-4 inhibitors exerted their 
renoprotective effect through anti-inflammation, 
antioxidativeStress and anti-fibrosis. 
Effects of Teneligliptin on lipid profiles34 - 38 
The lipid profile is an important determinant of 
cardiovascular risk in type 2 diabetes. It can affect 
antidiabetic therapy and is important in the clinical 
management of patients with type 2 diabetes. A potential 
beneficial effect of DPP-4 inhibitors on cholesterol, which 
could contribute to a reduction in cardiovascular risk. The 
administration of several DPP-4 inhibitors reduces post-
prandial triglyceride levels in humans, mice, and hamsters. 
Gliptins in combination with other oral 
antidiabetic agents39 - 42 
Since DPP-4 inhibitors and metformin improve glycemic 
control via different, albeit potentially complementary, 
mechanisms, combination therapy with these two agents 
should provide effective and potentially additive glycemic 
control. Studies using combination therapy of DPP-4 
inhibitors and metformin (as one pill) showed favorable 
results in glycemic control because of favorable 
pharmacokinetic characteristics and complementary 
pharmacodynamic effects, which include enhanced incretin 
effect, suppressed hepatic glucose production, and improved 
peripheral insulin sensitivity. Moreover, in general, the 
combination of this drug into a single tablet improves 
patients’ compliance and often results in a lower cost of 
treatment. 
Teneligliptin protects against 
hypoxia/reoxygenation-induced endothelialcell 
injury43 - 46 
Cardiovascular complications are the main causes of 
mortality in diabetic patients. Teneligliptin is a newly 
developed anti-diabetic agent. It has been reported that 
teneligliptin has a vascular protective capacity in preclinical 
studies and diabetes patient. The prevalence of diabetes 
mellitus has been a major threat to human health 
worldwide. The high prevalence of diabetes has increased 
the risk of serious diabetes-related complications. 
Diabetesassociated vascular diseases affect nearly all blood 
vessel types and sizes including arteries, veins and 
microvasculature. The long-time burden of diabetes often 
causes cardiovascular complications and ultimately, 
cardiovascular disease. Epidemiological data have shown 
that patients with type 2 diabetes mellitus have a 
considerable two to four fold higher risk of cardiovascular 
morbidity and mortality as compared with the non-diabetes 
population. It has been recognized that vascular 
complications are the cause of most morbidities, 
hospitalizations, and mortalities in diabetes patients. Curing 
cardiovascular complications and lowering glucose are the 
goals for an effective treatment for type 2 diabetes. Gliptins 
are a class of glucose-lowering agents for the treatment of 
type 2 diabetes. Recently, several kinds of gliptins have been 
shown to be effective in improving endothelial function, 
reducing oxidative and pro-inflammatory states, and 
exerting beneficial effects on cardiovascular function. 
Teneligliptin is one of the newly approved gliptins and has 
been shown be effective in treating type 2 diabetes. 
Interestingly, teneligliptin has displayed various cellular 
effects that are associated with vascular protection. It has 
been shown that teneligliptin can improve cardiac 
remodeling in hypertensive rats and improve endothelial 
dysfunction in prediabetic rats. A recent study demonstrated 
that teneligliptin inhibits atherogenesis in mice. In human 
subjects, administration of teneligliptin in diabetes patients 
improves patients’ endothelial function and heart function. 
Teneligliptin also regulates platelet-derived microparticles, 
suggesting that it possesses an anti-atherothrombotic effect 
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in patients with type 2 diabetes. Taken together, teneligliptin 
appears to be a very appealing anti-diabetic agent with the 
potent dual effects of reducing glucose and vascular 
protection. This versatile functional profile indicates that 
teneligliptin is a very promising drug for the control of 
diabetes as well as its vascular complications. 
The neurovascular protective effect of gliptin in 
murine MCAO modeland brain endothelial cells47, 
48 
Gliptinsare a novel class of treatment agents for diabetes, 
and recent studies have linked the use of gliptins to 
neuroprotection.Recently, studies have suggested that 
administrationof gliptins could exert neuroprotective effects 
in mice.A meta-analysis that included more than 9000 
human subjects concluded that gliptins may have certain 
protective effects in stroke condition. 
DPP-4 Inhibitors and Patient Weight49 - 52 
Studies on the influence of DPP-4 inhibitors on patient 
weight demonstrated variable results but are generally 
considered to be neutral. 
The Novel Dipeptidyl Peptidase-4 Inhibitor Teneligliptin 
Prevents High-Fat Diet-Induced Obesity Accompanied 
With Increased Energy Expenditure in Mice53 
Dipeptidyl peptidase-4 (DPP-4)-deficient mice exhibit 
prevention of obesity with increased energy expenditure. 
The novel DPP-4 inhibitor teneligliptin prevents obesity and 
obesity-related manifestations with increased energy 
expenditure. 
Conclusion 
All major guidelines recommend metformin as thefirst-line 
treatment in patients with diabetes. The American Diabetes 
Association (ADA) guidelines recommend dipeptidyl 
peptidase-4 as second-line therapy after metformin. 
Therefore, dipeptidyl peptidase-4 can be the choice of drugs 
in every T2D patient. Despite their common mechanism of 
action, DPP-4 inhibitors show marked structural, 
Pharmacokinetic and pharmacodynamic heterogeneity. 
Teneligliptin differs from other clinically used DPP-4 
inhibitors. Teneligliptin has a unique structure and binding 
site leading to enhanced potency and selectivity, imparts 
stronger inhibitory action on the DPP-4 enzyme. 
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